- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03117855
Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery
A Phase I Clinical Trial of Capecitabine and SIR-Spheres® Y-90-Radioembolization in Patients With Advanced Intrahepatic Cholangiocarcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the safety and toxicity of capecitabine, to be used in combination with yttrium Y-90 (yttrium 90) (Y-90) radioembolization (RE), in patients with a diagnosis of unresectable intrahepatic cholangiocarcinoma (ICC).
SECONDARY OBJECTIVES:
I. To describe the toxicities associated with Y-90 + capecitabine in patients with ICC.
II. To develop a preliminary assessment of efficacy by evaluating liver-specific progression-free survival (PFS) and overall PFS.
III. To develop a preliminary assessment of efficacy by evaluating response rate according to Response Evaluation Criteria in Solid Tumors (RECIST)/modified RECIST (mRECIST) and the Europeans Association for the Study of the Liver (EASL) imaging criteria.
IV. To develop a preliminary assessment of efficacy by evaluating cancer antigen (CA) 19-9 response and its correlation with imaging markers of tumor response.
V. To develop a preliminary assessment of efficacy by evaluating duration of response in the liver, as measured by the time for target liver lesions to progress according to RECIST/mRECIST beyond size at study enrollment.
VI. To develop a preliminary assessment of efficacy by evaluating rate of conversion to surgical resection for subjects who are surgically unresectable at presentation due to size or location of hepatic lesions (excluding subjects with extrahepatic disease or medically inoperable at presentation).
VII. To develop a preliminary assessment of efficacy by evaluating overall survival.
OUTLINE:
Patients undergo yttrium Y 90 resin microspheres radioembolization over 60-90 minutes on day 1. Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14.
After completion of study treatment, patients are followed up every 2 months.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented informed consent of the participant and/or legally authorized representative
- Eastern Cooperative Oncology Group performance status 0-2
- Life expectancy > 3 months
- Intrahepatic cholangiocarcinoma; a histological diagnosis is mandated; a diagnosis of adenocarcinoma with staining pattern consistent with cholangiocarcinoma and with a clinical presentation consistent with cholangiocarcinoma will be acceptable for enrollment as this is a typical intrahepatic cholangiocarcinoma presentation
- Primary tumor deemed unresectable by hepatobiliary surgeon
Absence of the following:
- Malignant ascites
- Extensive carcinomatosis (in the opinion of the investigator)
- Bulky, diffuse adenopathy (> 5 lymph nodes > 2 cm each)
- Extensive metastatic disease to the lungs (> 5 tumors > 2 cm each)
Has completed pre-RE angiogram up to 3 weeks prior to Y-90 therapy
- Lung shunt fraction =< 20% and anatomy amenable to intra-arterial radiation delivery
- Extrahepatic vessels deemed at risk for radiation injury were successfully embolized
- Prior systemic chemotherapy must be completed > 2 weeks of radioembolization
- Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only)
- Platelets (PLT) >= 100,000/mm^3
- Absolute neutrophil count (ANC) >= 1500 cells/mm^3
- Creatinine clearance of > 50 mL/min per 24 hour urine collection of the Cockcroft-Gault formula
- Hemoglobin > 9 g/dL
- Total bilirubin < 2 mg/dL
- Agreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and until at least 180 days after administration of any study agent; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
Exclusion Criteria:
- Prior selective internal radiation to the liver
- Prior warfarin-based therapies within 7 days of capecitabine treatment
- Actively receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy
- Neuropathy >= grade 2 (moderate neuropathy that limits instrumental activities of daily living)
- History of main or lobar portal vein thrombosis
- History of biliary stent, internal biliary drain, or prior procedure compromising the ampulla of Vater (diagnostic endoscopic retrograde cholangiopancreatography [ERCP] is permissible)
- Known dihydropyrimidine dehydrogenase deficiency
History of allergic reactions attributed to:
- Study agent or its metabolites
- Iodinated contrast media
- Pregnant or breastfeeding (women)
- Concurrent diagnosis of other active malignancies with the exception of ductal carcinoma in situ, cervical carcinoma in situ, and localized non-melanoma skin cancer
- Any clinically significant uncontrolled illness including ongoing active infection
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment (capecitabine, yttrium Y-90 radioembolization)
Patients undergo yttrium Y 90 resin microspheres radioembolization over 60-90 minutes on day 1.
Patients receive capecitabine PO BID on days 1-14.
|
Correlative studies
Given PO
Other Names:
Undergo yttrium Y-90 radioembolization
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of dose limiting toxicities (DLT) defined as any grade 3 or above toxicity assessed by the National Cancer Institute Common Terminology for Adverse Events version 4.0
Time Frame: Up to day 45
|
The toxicities observed at each dose level will be summarized in terms of type, severity, time of onset, duration, and reversibility or outcome.
Tables will be created to summarize these toxicities.
Tabular and graphical summaries will be used to explore the relationship of type and grade toxicity to other clinical parameters such as disease response and the presence of other comorbidities.
|
Up to day 45
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response according to RECIST v1.1, mRECIST, and EASL criteria
Time Frame: Time until tumors progress beyond the values measured at baseline, assessed up to 48 months
|
Duration of response will be calculated independently of PFS in order to evaluate the possibility that progression may occur after an initial tumor shrinkage.
|
Time until tumors progress beyond the values measured at baseline, assessed up to 48 months
|
Levels of CA 19-9 response
Time Frame: Up to 48 months
|
CA 19-9 will be assessed after Y-90 and will be compared to other measures of disease response using Pearson correlation or similar methods.
|
Up to 48 months
|
Liver-specific PFS according to RECIST v1.1, mRECIST, and EASL criteria
Time Frame: Time until tumors progress beyond the values measured at baseline, assessed up to 48 months
|
Evaluated using Kaplan-Meier analysis.
|
Time until tumors progress beyond the values measured at baseline, assessed up to 48 months
|
Overall survival
Time Frame: Up to 48 months
|
Evaluated using Kaplan-Meier analysis.
|
Up to 48 months
|
PFS according to RECIST v1.1, mRECIST, and EASL criteria
Time Frame: Time until tumors progress beyond the values measured at baseline, assessed up to 48 months
|
Evaluated using Kaplan-Meier analysis.
|
Time until tumors progress beyond the values measured at baseline, assessed up to 48 months
|
Rate of conversion to surgical candidacy
Time Frame: Up to 48 months
|
Up to 48 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jonathan Kessler, MD, City of Hope Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neoplasms, Ductal, Lobular, and Medullary
- Cholangiocarcinoma
- Carcinoma, Ductal
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Capecitabine
Other Study ID Numbers
- 16148 (OTHER: City of Hope Medical Center)
- NCI-2016-01098 (REGISTRY: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bile Duct Adenocarcinoma
-
AIO-Studien-gGmbHServier; Institut für Klinisch-Onkologische Forschung der Krankenhaus Nordwest...Active, not recruitingBiliary Tract Cancer | Extrahepatic Bile Duct Carcinoma | Non-Resectable Hepatocellular Carcinoma | Adenocarcinoma Metastatic | Adenocarcinoma of the Biliary Tract | Adenocarinoma Locally Advanced | Intrahepatic Bile Duct CarcinomaGermany
-
Zhejiang Cancer HospitalRecruitingHER2 Gene Mutation | Bile Duct Adenocarcinoma Non-ResectableChina
-
Innovative Digestive Health Education and Research...NinePoint MedicalUnknownCholangiocarcinoma | Bile Duct Cancer | Primary Sclerosing Cholangitis | Bile Duct Diseases | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer | Bile Duct Neoplasms | Biliary Stricture | Bile Duct Obstruction | Bile Duct Obstruction, Extrahepatic | Pancreatic Duct Stricture | Bile Duct Lesions | Bile Duct Neoplasms... and other conditionsUnited States
-
Gangnam Severance HospitalKorea Institute of Science and TechnologyCompletedBile Duct Obstruction, ExtrahepaticKorea, Republic of
-
National Cancer Institute (NCI)CompletedHilar Cholangiocarcinoma | Recurrent Gallbladder Carcinoma | Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Gallbladder Adenocarcinoma | Recurrent Extrahepatic Bile Duct Carcinoma | Extrahepatic Bile Duct Adenocarcinoma | Gallbladder Adenocarcinoma With Squamous... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedMalignant Neoplasm | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adenocarcinoma of the Gallbladder | Adenocarcinoma of the Extrahepatic Bile DuctUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct | Cholangiocarcinoma of the Gallbladder | Adenocarcinoma of the Gallbladder | Adenocarcinoma With... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Gallbladder Carcinoma | Metastatic Gallbladder Carcinoma | Stage IV Gallbladder Cancer AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Recurrent Intrahepatic Cholangiocarcinoma | Metastatic... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingBile Duct Cancer | Biliary Cancer | Cancer of the Bile DuctUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingLiver and Intrahepatic Bile Duct CarcinomaUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States